Evidence map›Paper›PMID 35550267›Full record

ReviewThe Lancet. Oncology2022

Cancer in sub-Saharan Africa: a Lancet Oncology Commission.

Wilfred Ngwa, Beatrice W Addai, Isaac Adewole, Victoria Ainsworth, James Alaro, Olusegun I Alatise, Zipporah Ali, Benjamin O Anderson, Rose Anorlu, Stephen Avery and 43 more

Registry-linked trialAbstract readReview
In one paragraph

Review in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928909 (Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi), which is not on this map. Cited by 203 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
203citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06928909 recruitingnot on this mapstarted 2025, after this paper: background citation

Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi

TypeobservationalSponsorBaylor College of MedicineRan2025 to 2030Enrolled30ConditionsAcute Myeloid LeukaemiaArmsIntensity-adapted pediatric acute myeloid treatment guidelines
3 · Its place in the literature

Who cites it

203 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Cervical cancer survival times in Africa.Frontiers in public health · 2022
    Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

143 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

53 authors.

Wilfred NgwaBrigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Sidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Information and Sciences, ICT University, Yaoundé, Cameroon. Electronic address: wngwa1@jhmi.edu.
Beatrice W AddaiBreast Care International, Peace and Love Hospital, Kumasi, Ghana.
Isaac AdewoleCollege of Medicine, University of Ibadan, Ibadan, Nigeria.
Victoria AinsworthDepartment of Physics and Applied Physics, University of Massachusetts Lowell, Lowell, MA, USA.
James AlaroNational Cancer Institute, National Institute of Health, Bethesda, MD, USA.
Olusegun I AlatiseDepartment of Surgery, Obafemi Awolowo University, Ile Ife, Nigeria.
Zipporah AliKenya Hospices and Palliative Care Association, Nairobi, Kenya.
Benjamin O AndersonDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Non-communicable Diseases, WHO, Geneva, Switzerland.
Rose AnorluDepartment of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria.
Stephen AveryDepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Prebo BarangoWHO, Regional Office for Africa, Brazzaville, Republic of the Congo.
Noella BihDana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Christopher M BoothDivision of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada.
Otis W BrawleySidney Kimmel Comprehensive Cancer Center, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Jean-Marie DangouWHO, Regional Office for Africa, Brazzaville, Republic of the Congo.
Lynette DennyDepartment of Obstetrics and Gynaecology, University of Cape Town, Cape Town, South Africa; South African Medical Research Council, Gynaecological Cancer Research Centre, Tygerberg, South Africa.
Jennifer DentBIO Ventures for Global Health, Seattle, WA, USA.
Shekinah N C ElmoreDepartment of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Ahmed ElzawawyDepartment of Clinical Oncology, Suez Canal University, Ismailia, Egypt.
Diane GashumbaMinistry of Health, Kigali, Rwanda.
Jennifer GeelDivision of Paediatric Haematology and Oncology, Faculty of Health Sciences, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Katy GraefBIO Ventures for Global Health, Seattle, WA, USA.
Sumit GuptaDivision of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Serigne-Magueye GueyeUrology Department, Idrissa Pouye General Hospital, Dakar, Senegal.
Nazik HammadDepartment of Oncology, Queen's University, Kingston, ON, Canada.
Laila HessissenPediatric Oncology Department, Pediatric Teaching Hospital, Rabat, Morocco.
Andre M IlbawiDepartment of Non-communicable Diseases, WHO, Geneva, Switzerland.
Joyce KambuguDepartment of Pediatrics, Uganda Cancer Institute, Kampala, Uganda.
Zisis KozlakidisLaboratory Services and Biobank Group, International Agency for Research on Cancer, WHO, Lyon, France.
Simon MangaCameroon Baptist Convention Health Services, Bamenda, Cameroon.
Lize MareeDepartment of Nursing Education, University of the Witwatersrand, Johannesburg, South Africa.
Sulma I MohammedDepartment of Comparative Pathobiology, Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Susan MsadabweDepartment of Radiation Therapy, Cancer Diseases Hospital, Lusaka, Zambia.
Miriam MutebiDepartment of Surgery, Aga Khan University Hospital, Nairobi, Kenya.
Annet NakagandaUganda Cancer Institute, Kampala, Uganda.
Ntokozo NdlovuFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Kingsley NdohDepartment of Global Health, University of Washington, Seattle, WA, USA.
Jerry NdumbaloOcean Road Cancer Institute, Dar es Salaam, Tanzania.
Mamsau NgomaOcean Road Cancer Institute, Dar es Salaam, Tanzania.
Twalib NgomaDepartment of Clinical Oncology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Christian NtizimiraAfrican Centre for Research on End-of-Life Care, Kigali, Rwanda.
Timothy R RebbeckDana-Farber Cancer Institute, Harvard T H Chan School of Public Health, Boston, MA, USA.
Lorna RennerDepartment of Paediatrics, University of Ghana School of Medicine and Dentistry, Accra, Ghana.
Anya RomanoffDepartment of Health System Design and Global Health, Icahn School of Medicine, The Mount Sinai Hospital, New York, NY, USA.
Fidel RubagumyaDepartment of Oncology, Rwanda Military Hospital, Kigali, Rwanda; University of Global Health Equity, Kigali, Rwanda.
Shahin SayedDepartment of Pathology, Aga Khan University Hospital, Nairobi, Kenya.
Shivani SudDepartment of Radiation Oncology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Hannah SimondsDivision of Radiation Oncology, Tygerberg Hospital and University of Stellenbosch, Stellenbosch, South Africa.
Richard SullivanInstitute of Cancer Policy, King's College London, London, UK.
William SwansonDepartment of Physics and Applied Physics, Dana-Farber Cancer Institute, University of Massachusetts Lowell, Lowell, MA, USA.
Verna VanderpuyeNational Centre for Radiotherapy, Oncology, and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana.
Boateng WiafeWatborg Eye Services, Obutu, Ghana.
David KerrRadcliffe Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Funding

Nutritional Assessment of Cancer Risk in African MenU01CA184374 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2015 to 2019
$9.1M
Precision Assessment and Delivery of Cancer Risks in BRCA 1/2 Mutation CancersR01CA207365 · NCI · DANA-FARBER CANCER INST · PI CHEN, JINBO, REBBECK, TIMOTHY R · 2017 to 2021
$3.6M
Precision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2M
Global Health Catalyst (GHC) SummitR13CA257481 · NCI · UNIVERSITY OF PENNSYLVANIA · PI AVERY, STEPHEN, NGWA, WILFRED · 2021 to 2022
$40k
Medical Research Council MR/P025420/1NCI NIH HHS P20 CA233255NCI NIH HHS R01 CA207365NCI NIH HHS R13 CA257481NCI NIH HHS U01 CA184374World Health Organization 001
6 · The paper itself

Abstract

In sub-Saharan Africa (SSA), urgent action is needed to curb a growing crisis in cancer incidence and mortality. Without rapid interventions, data estimates show a major increase in cancer mortality from 520 348 in 2020 to about 1 million deaths per year by 2030. Here, we detail the state of cancer in SSA, recommend key actions on the basis of analysis, and highlight case studies and successful models that can be emulated, adapted, or improved across the region to reduce the growing cancer crises. Recommended actions begin with the need to develop or update national cancer control plans in each country. Plans must include childhood cancer plans, managing comorbidities such as HIV and malnutrition, a reliable and predictable supply of medication, and the provision of psychosocial, supportive, and palliative care. Plans should also engage traditional, complementary, and alternative medical practices employed by more than 80% of SSA populations and pathways to reduce missed diagnoses and late referrals. More substantial investment is needed in developing cancer registries and cancer diagnostics for core cancer tests. We show that investments in, and increased adoption of, some approaches used during the COVID-19 pandemic, such as hypofractionated radiotherapy and telehealth, can substantially increase access to cancer care in Africa, accelerate cancer prevention and control efforts, increase survival, and save billions of US dollars over the next decade. The involvement of African First Ladies in cancer prevention efforts represents one practical approach that should be amplified across SSA. Moreover, investments in workforce training are crucial to prevent millions of avoidable deaths by 2030. We present a framework that can be used to strategically plan cancer research enhancement in SSA, with investments in research that can produce a return on investment and help drive policy and effective collaborations. Expansion of universal health coverage to incorporate cancer into essential benefits packages is also vital. Implementation of the recommended actions in this Commission will be crucial for reducing the growing cancer crises in SSA and achieving political commitments to the UN Sustainable Development Goals to reduce premature mortality from non-communicable diseases by a third by 2030.

Indexed as

COVID-19NeoplasmsNoncommunicable DiseasesAfrica South of the SaharaChildDelivery of Health CareHumansPandemics

Identifiers

PMID35550267
PMCPMC9393090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.